Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25265974 | 0.98 | TSHR (0.57) | TSHRDNM1ALDH1A1THRBLMNA | |
| Methacrylic Acid SCHEMBL2580360 | 0.96 | TSHR (0.54) | TSHRDNM1ALDH1A1THRBLMNA | |
| SCHEMBL9767545 | 0.94 | TSHR (0.69) | TSHRDNM1ALDH1A1THRBLMNA | |
| SCHEMBL3366486 | 0.94 | TSHR (0.69) | TSHRDNM1ALDH1A1THRBLMNA | |
| SCHEMBL8424369 | 0.94 | TSHR (0.66) | TSHRDNM1ALDH1A1THRBLMNA | |
| SCHEMBL1704602 | 0.94 | TSHR (0.66) | TSHRDNM1ALDH1A1THRBLMNA | |
| SCHEMBL28482639 | 0.91 | TSHR (0.55) | TSHRDNM1ALDH1A1THRBLMNA | |
| Cadaverine Tartrate SCHEMBL25213297 | 0.91 | TSHR (0.49) | TSHRDNM1ALDH1A1THRBLMNA | |
| SCHEMBL27387413 | 0.91 | TSHR (0.55) | TSHRDNM1ALDH1A1THRBLMNA | |
| SCHEMBL2807372 | 0.91 | ALDH1A1 (0.56) | TSHRDNM1ALDH1A1THRBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118311082-A | Alanine dosimeter microchip for ESR electron spin resonance spectrometer | 上海金鹏源辐照技术有限公司 | 2024-07-09 | — | — | CN | claimed |
| US-20240041844-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING HELICOBACTERACEAE INFECTIONS | UNIVERSITY OF OREGON (US) | 2024-02-08 | — | — | US | claimed |
| EP-2793866-B2 | BILAYER TABLET COMPRISING BENAZEPRIL HYDROCHLORIDE AND PIMOBENDAN | ELANCO TIERGESUNDHEIT AG (CH) | 2023-10-25 | — | — | EP | claimed |
| CN-116940346-A | Solid dispersion | 益方生物科技(上海)股份有限公司 | 2023-10-24 | — | — | CN | claimed |
| WO-2023193244-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | 北京睿创康泰医药研究院有限公司 | 2023-10-12 | — | — | WO | claimed |
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | AMGEN INC. (US) | 2023-10-05 | — | — | US | claimed |
| EP-4203922-A1 | MCL-1 INHIBITOR FORMULATIONS | Amgen Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116113473-A | MCL-1 inhibitor formulations | 安进公司 | 2023-05-12 | — | — | CN | claimed |
| EP-4106828-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | GIE Medical, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| CN-114681392-A | Sustained-release oral solid composition | 江苏恒瑞医药股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20070190124-A1 | Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs | NUVO RESEARCH INC. (CA) | 2007-08-16 | — | — | US | claimed |
| US-20070189977-A1 | Spray-on formulations and methods for dermal delivery of drugs | ZARS, INC. | 2007-08-16 | — | — | US | claimed |
| US-20070189978-A1 | Compositions and methods for dermally treating musculoskeletal pain | ZARS, INC. | 2007-08-16 | — | — | US | claimed |
| WO-2007070679-A2 | COMPOSITIONS AND METHODS FOR DERMALLY TREATING PAIN | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070695-A2 | FLUX-ENABLING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070643-A2 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070694-A2 | SPRAY-ON FORMULATIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| CN-1555256-A | Pharmaceutical formulation comprising a proton pump inhibitor and antacids | — | 2004-12-15 | — | — | CN | claimed |
| US-20030129131-A1 | Preparations for measuring gastric ph value and method of measuring gastric ph value by using the same | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2003-07-10 | — | — | US | claimed |
| EP-1312381-A1 | PREPARATIONS FOR MEASRUING GASTRIC pH VALUE AND METHOD OF MEASURING GASTRIC pH VALUE BY USING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041844-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING HELICOBACTERACEAE INFECTIONS | PRDX3, GPX1, POR | TSHR 2131/4885DNM1 4358/4885ALDH1A1 578/4885 |
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | MCL1, BAK1, BCL2L1 | TSHR 4494/4885DNM1 244/4885ALDH1A1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.